Today’s leading autoimmune/inflammatory disease drugs are blockbusters, but what are the remaining unmet needs and next opportunities? Dealmaking patterns indicate that Big Pharma continues to look to small technology companies to tap opportunities to treat underserved diseases and offer improved administration options. While the value of the novel agents in development remains unproved, earlystage platforms and pipelines house the next innovations in these disease states.
Get the Answers You Need to Shape Your Strategy
Although efficacious, current therapies for inflammatory and autoimmune diseases do not successfully
treat all patients. What novel mechanisms of action are in development? What technologies offer treatment potential?
Much of the innovation in drug discovery and design occurs in small companies. What companies are developing novel approaches to treat inflammatory diseases? What collaborations have they forged with Big Pharma?
Although the inflammatory cascade is central to most of the autoimmune diseases, the specific etiology
of many diseases remains unknown. What are companies doing to further the understanding of these diseases?
Scope
Current market: 2008 sales, market-leading products, leading companies.
Novel targets for drug development: MAP kinases, Janus kinases, toll-like receptors,novel interleukins, NF-êB, PDE4.
Novel technologies for drug development: RNA therapeutics, stem-cell therapy.
Development and dealmaking data: 8 tables that identify developmental compounds and industry and academic alliances.
Company profiles: Archemix, Array BioPharma, Cellzome, Dynavax, Regulus Therapeutics.
(0 items)
